Last Updated : October 10, 2024
Details
| Call for patient/clinician input open | 07-Mar-24 |
|---|---|
| Call for patient/clinician input closed | 30-Apr-24 |
| Clarification: - Patient input submission received from the Canadian Immunodficiencies Patient Organization (operating as Immunity Canada) | |
| Submission received | 19-Apr-24 |
| Submission accepted | 06-May-24 |
| Review initiated | 07-May-24 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 22-Jul-24 |
| Clarification: - Submission temporarily suspended | |
Details
| Call for patient/clinician input open | 06-Mar-24 |
|---|---|
| Call for patient/clinician input closed | 30-Apr-24 |
| Clarification: - Patient input submission received from Myeloma Canada | |
| Submission received | 18-Apr-24 |
| Submission accepted | 03-May-24 |
| Review initiated | 06-May-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 24-Jul-24 |
| Deadline for sponsors comments | 02-Aug-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 29-Aug-24 |
| Expert committee meeting (initial) | 11-Sep-24 |
| Draft recommendation issued to sponsor | 24-Sep-24 |
| Draft recommendation posted for stakeholder feedback | 03-Oct-24 |
| End of feedback period | 18-Oct-24 |
| Final recommendation issued to sponsor and drug plans | 01-Nov-24 |
| Final recommendation posted | 20-Nov-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 18-Nov-24 |
| CDA-AMC review report(s) posted | 31-Mar-25 |
Last Updated : April 1, 2025
Details
| Call for patient/clinician input open | 06-Mar-24 |
|---|---|
| Call for patient/clinician input closed | 30-Apr-24 |
| Clarification: - Patient input submission received from Lung Cancer Canada and the Lung Health Foundation / Ontario Lung Association | |
| Submission received | 18-Apr-24 |
| Submission accepted | 03-May-24 |
| Review initiated | 06-May-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 24-Jul-24 |
| Deadline for sponsors comments | 02-Aug-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 29-Aug-24 |
| Expert committee meeting (initial) | 11-Sep-24 |
| Draft recommendation issued to sponsor | 23-Sep-24 |
| Draft recommendation posted for stakeholder feedback | 03-Oct-24 |
| End of feedback period | 18-Oct-24 |
| Final recommendation issued to sponsor and drug plans | 30-Oct-24 |
| Final recommendation posted | 18-Nov-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 14-Nov-24 |
| CDA-AMC review report(s) posted | 05-Mar-25 |
Last Updated : May 2, 2025
Details
Program Updates
1. Pilot Expert Committee Extension and Upcoming Call for Nominations
Canada's Drug Agency is pleased to announce a 1-year extension to the Formulary Management Expert Committee (FMEC), the new expert committee announced as a 1-year pilot in June 2023.
Last Updated : February 29, 2024
Details
| Call for patient/clinician/industry input open | February 12, 2024 |
|---|---|
| Call for patient/clinician/industry input closed | April 22, 2024 |
| Submission received | February 12, 2024 |
| Review initiated | February 13, 2024 |
| Expert committee meeting (initial) | July 04, 2024 |
| Draft recommendation posted for stakeholder feedback | August 01, 2024 |
| End of feedback period | August 16, 2024 |
| Final recommendation posted | September 24, 2024 |
| Canada's Drug Agency review report(s) posted | August 21, 2024 |
Last Updated : October 30, 2024
Details
| Call for patient/clinician input open | February 27, 2024 |
|---|---|
| Call for patient/clinician input closed | April 22, 2024 |
| Clarification: - Patient input submission received from Transthyretin Amyloidosis Canada (TAC) | |
| Submission received | April 09, 2024 |
| Submission accepted | April 23, 2024 |
| Review initiated | April 24, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | July 10, 2024 |
| Deadline for sponsors comments | July 19, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | August 16, 2024 |
| Expert committee meeting (initial) | August 28, 2024 |
| Draft recommendation issued to sponsor | September 12, 2024 |
| Draft recommendation posted for stakeholder feedback | September 19, 2024 |
| End of feedback period | October 04, 2024 |
| Final recommendation issued to sponsor and drug plans | October 21, 2024 |
| Final recommendation posted | November 06, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 04, 2024 |
| CADTH review report(s) posted | February 18, 2025 |
Last Updated : February 19, 2025